NCT05439564View on ClinicalTrials.gov

Intrathecal Morphine Versus Morphine-dexmedetomidine Combination for Postoperative Pain Control After Total Knee Replacement

NACompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

January 30, 2023

Conditions
Intrathecal MorphineIntrathecal Morphine-dexmedetomidine CombinationPostoperative Pain ControlTotal Knee Replacement
Interventions
DRUG

Dexmedetomidine

Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.

DRUG

Morphine

Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.

DRUG

Dexmedetomidine

Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.

Trial Locations (1)

Unknown

Faculty of Medicine, Tantan University Hospital, Tanta

All Listed Sponsors
lead

Tanta University

OTHER